Mallia Innovations Charts Future with €5.5 Million Financing

Mallia Innovations GmbH has announced a strategic reorganization and completed €5.5 million in financing to focus on hair loss treatments. The company will now operate as a holding entity for two subsidiaries, concentrating on medical and cosmetic applications. The subsidiaries, Mallia Therapeutics and the newly established Mallia Aesthetics, will focus on clinical therapies and cosmetic innovations, respectively.

Mallia Aesthetics, led by Dr. Anne Asmuß and Dr. Manfred Gröppel, will develop cosmetic products using the promising ingredient MAL-838, targeting a broad market by 2025. Mallia Therapeutics, under the guidance of Dr. Stefan Strobl, will continue the development of the sCD83-based therapy MAL-856 for conditions like androgenetic alopecia.

By leveraging the €5.5 million in new funding, Mallia aims to expedite the development of patent-protected cosmetic products and innovative therapies. This strategic realignment underscores Mallia’s commitment to bringing new solutions for hair growth and loss to the market.